ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2033

Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease

Guy Katz1, Judith Ferry1, Grace McMahon1, Isha Jha2, Claire Galand3, Fei Liu4, Shelia Violette4, Jason Campagna4, Ana Fernandes1, Cory Perugino5 and John Stone6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Q32 Bio Inc,, Waltham, MA, 4Q32 Bio Inc, Waltham, MA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, 6Massachusetts General Hospital , Harvard Medical School, Concord, MA

Meeting: ACR Convergence 2025

Keywords: complement, IgG4 Related Disease, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Hypocomplementemia, defined as low serum C3 and/or C4 concentrations, is common in patients with IgG4-related disease (IgG4-RD). While this has historically been linked with renal involvement, recent data have shown that hypocomplementemia is more accurately associated with extent of IgG4-RD across multiple sites rather than individual organ manifestations, suggesting that complement-driven inflammation is central to the disease process. We aimed to assess whether complement is deposited locally in IgG4-RD submandibular gland lesions.

Methods: We obtained submandibular gland tissue from 8 patients who fulfilled the 2019 ACR/EULAR IgG4-RD Classification Criteria and had undergone submandibular gland biopsy for diagnostic purposes. Other disease features, including sites of involvement beyond the submandibular glands and the presence or absence of hypocomplementemia, were not considered when identifying samples to be analyzed. We extracted disease features, laboratory results, demographic data, and treatment status at the time of biopsy from the medical records. All tissues were formalin-fixed and paraffin-embedded prior to sectioning. Immunohistochemistry was performed to stain for C3d, an end product of complement activation that persists in tissue longer than most other complement activation fragments. We similarly stained for C3d in a negative control (uninvolved submandibular gland) and positive control (human liver with primary sclerosing cholangitis).

Results: Demographic and disease characteristics of the 8 IgG4-RD patients studied are shown in Table 1. Six of the 8 patients (75%) were treatment-naïve at the time the biopsies were obtained. Five (62.5%) of the patients were female. The median disease duration at the time of biopsy was 301.5 days (IQR: 221, 1082.5). Only 3 patients (37.5%) had hypocomplementemia at any point in the disease course. Histopathologic features of the submandibular glands are shown in Table 2 and reflect the findings that are typical of submandibular glands involved by IgG4-RD. All samples demonstrated a dense lymphoplasmacytic infiltrate and most (5, 62.5%) demonstrated an IgG4+/IgG+ plasma cell ratio ≥40% (Figure 1A-D). All 8 submandibular gland biopsies showed deposition of C3d at sites of immune infiltration (Figure 1E-F), suggesting immune cells may be triggering complement activation. Additionally, C3d was also observed in several sites of fibrosis, suggesting complement may be contributing to fibrosis in IgG4-RD (Figure 1F-H). Staining patterns of positive and negative controls were as expected (Figure 1I-J).

Conclusion: Evidence of complement deposition was found in 8 of 8 submandibular glands included in this study. Complement activation was evident at this site of disease even in patients who demonstrated no sign of complement consumption in the peripheral blood (i.e., no C3 or C4 hypocomplementemia). These findings raise the possibility that tissue-targeted complement inhibition may be a useful treatment strategy in IgG4-RD and support the notion of complement-mediated inflammation being central to the disease mechanism of IgG4-RD.

Supporting image 1Table 1. Demographics and disease characteristics of eight patients in whom submandibular gland biopsies were stained for complement deposition. Results reported as n (%) unless noted otherwise. §At any point in disease course. *1 patient was treated with methotrexate for comorbid rheumatoid arthritis.

Supporting image 2

Supporting image 3Figure 1. Representative histopathology and immunostaining findings. (A) Low- and (B) high-powered hematoxylin and eosin stain of diseased submandibular glands (SMG) showing dense lymphoplasmacytic infiltrate. (C) IgG and (D) IgG4 stains of diseased SMG showing a large proportion of IgG4+ plasma cells. (E-H) C3d staining of diseased SMG showing C3d staining at sites of inflammation and fibrosis. (I) C3d stain of an uninvolved SMG (negative control) showing absent C3d staining. (J) C3d stain of human liver with primary sclerosing cholangitis (positive control) showing expected pattern of staining.


Disclosures: G. Katz: Acepodia, 1, Amgen, 1, 2, 5, Sana, 5, Sanofi, 5, Zenas, 5; J. Ferry: None; G. McMahon: None; I. Jha: None; C. Galand: Q32 Bio, 3; F. Liu: Q32 Bio, 12,, 3; S. Violette: Mediar Therapeutics, 12,, 1, Q32 Bio, 12,, 3, 8, 10, Triveni, 12,, 1; J. Campagna: None; A. Fernandes: None; C. Perugino: Acepodia, 2, Amgen, 1, 2, Bristol-Myers Squibb, 2, Sanofi, 2, Zenas Biopharma, 2; J. Stone: Acepodia, 2, Amgen, 1, 2, argenx, 2, Bristol-Myers Squibb, 2, Novartis, 2, Q32 Bio, 2, Sanofi, 2, Zenas, 2.

To cite this abstract in AMA style:

Katz G, Ferry J, McMahon G, Jha I, Galand C, Liu F, Violette S, Campagna J, Fernandes A, Perugino C, Stone J. Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/complement-fragments-are-deposited-in-the-submandibular-glands-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-fragments-are-deposited-in-the-submandibular-glands-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology